MedTrace Logo

The Effect of Simvastatin on Desensitization of Panel-Positive Kidney Transplant Candidates

NCT00693576 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2008-06-09

No results posted yet for this study

Summary

Patients with panel reactive antibodies have many difficulties to find a crossmatch-negative kidney for transplantation and are at the risk of post transplantation rejection more than other transplanted patients. We evaluated the effect of simvastatin on PRA and post transplant outcome of these sensitized patients. We also performed a descriptive study.

Conditions

  • Renal Transplantation

Interventions

DRUG

simvastatin

20 mg simvastatin daily

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Principal Investigators

  • jamshid roozbeh, associate professor · shiraz university of medical science

  • azar Sattarinezhad, internal medicine resident · shiraz university of medical science,internal medicine department

  • mohammad mahdi sagheb, assistant professor · Shiraz University of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00693576 on ClinicalTrials.gov